St. Lukes Hospital Of Duluth
- Type
- Teaching hospital
- Where
- Duluth, MN
- Medicare CCN
- 240047
- Received
- $350,638 in 91 records, 2023 ($177,048 general, $173,590 research)
- Source
- CMS Open Payments search ↗
On this site
- Plan sponsor: ST. LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
- Federal award recipient: ST LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
- Nonprofit: ST LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 50 | $177,048 |
| 2023 | Research payment | 41 | $173,590 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| CardioFocus, Inc. | 1 | $150,000 | 2023 |
| AstraZeneca Pharmaceuticals LP | 5 | $114,951 | 2023 |
| ABBVIE INC. | 18 | $30,222 | 2023 |
| Smith+Nephew, Inc. | 37 | $16,993 | 2023 |
| PFIZER INC. | 1 | $10,750 | 2023 |
| AstraZeneca UK Limited | 2 | $7,233 | 2023 |
| Medline Industries LP | 1 | $4,417 | 2023 |
| Eli Lilly and Company | 1 | $3,500 | 2023 |
| Olympus America Inc. | 1 | $3,329 | 2023 |
| Boston Scientific Corporation | 7 | $3,108 | 2023 |
| CSL Behring | 5 | $3,100 | 2023 |
| Baxter Healthcare | 1 | $1,351 | 2023 |
| Linvatec Corporation | 1 | $513 | 2023 |
| Janssen Research & Development, LLC | 1 | $500 | 2023 |
| Stryker Corporation | 7 | $419 | 2023 |
| Philips North America LLC | 1 | $225 | 2023 |
| Merge Healthcare Incorporated | 1 | $24 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 41 | $173,590 |
| Long term medical supply or device loan | 42 | $168,377 |
| Debt forgiveness | 7 | $8,647 |
| Food and Beverage | 1 | $24 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Medline Industries LP | $4,417 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $559 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2023 |
| 2023-12-31 | Linvatec Corporation | $513 | Long term medical supply or device loan | In-kind items and services | AIRSEAL Device, GENERAL SURGERY | 2023 | |
| 2023-12-31 | AstraZeneca UK Limited | $253 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphami | 2023 |
| 2023-12-31 | Stryker Corporation | $163 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Stryker Corporation | $49 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Stryker Corporation | $41 | Long term medical supply or device loan | In-kind items and services | WALL-SAVER RECLINER Device, FURNITURE | 2023 | |
| 2023-12-31 | Stryker Corporation | $41 | Long term medical supply or device loan | In-kind items and services | WALL-SAVER RECLINER Device, FURNITURE | 2023 | |
| 2023-12-31 | Stryker Corporation | $41 | Long term medical supply or device loan | In-kind items and services | WALL-SAVER RECLINER Device, FURNITURE | 2023 | |
| 2023-12-31 | Stryker Corporation | $41 | Long term medical supply or device loan | In-kind items and services | WALL-SAVER RECLINER Device, FURNITURE | 2023 | |
| 2023-12-31 | Stryker Corporation | $41 | Long term medical supply or device loan | In-kind items and services | WALL-SAVER RECLINER Device, FURNITURE | 2023 | |
| 2023-12-29 | Smith+Nephew, Inc. | $404 | Debt forgiveness | Cash or cash equivalent | FAST-FIX Device, Sports Med Knee | 2023 | |
| 2023-12-29 | Smith+Nephew, Inc. | $271 | Debt forgiveness | Cash or cash equivalent | Bone Anchors with Arthroscopic Delivery System Device, Extremities & Limb Restoration | 2023 | |
| 2023-12-21 | Eli Lilly and Company | $3,500 | Research payment | Cash or cash equivalent | AN OPEN-LABEL MULTI-CENTER PATIENT ACCESS PROGRAM OF OLARATUMAB FOR THE TREATMENT OF SOFT TISSUE SARCOMA | 2023 | |
| 2023-12-13 | ABBVIE INC. | $2,684 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-12-13 | ABBVIE INC. | $1,636 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-12-13 | ABBVIE INC. | $1,465 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-12-13 | ABBVIE INC. | $868 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-12-13 | ABBVIE INC. | $750 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2023 |
| 2023-12-13 | ABBVIE INC. | $750 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-12-13 | ABBVIE INC. | $750 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2023 |
| 2023-12-11 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2023 | |
| 2023-12-11 | CSL Behring | $350 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2023 | |
| 2023-11-17 | CSL Behring | $500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2023 | |
| 2023-11-03 | Olympus America Inc. | $3,329 | Debt forgiveness | In-kind items and services | EVIS EXERA lll COLONOVIDEOSCOPE Device, Gastroenterology | 2023 | |
| 2023-10-02 | Boston Scientific Corporation | $507 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-08-29 | Merge Healthcare Incorporated | $24 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2023 | |
| 2023-08-08 | Boston Scientific Corporation | $750 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-08-08 | Boston Scientific Corporation | $113 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-07-20 | ABBVIE INC. | $750 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-07-20 | ABBVIE INC. | $480 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-07-20 | ABBVIE INC. | $150 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-07-06 | Philips North America LLC | $225 | Research payment | In-kind items and services | (6571) Eagle Eye Device, Medical Device | IMPROVE | 2023 |
| 2023-07-03 | Boston Scientific Corporation | $357 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-06-13 | ABBVIE INC. | $750 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2023 |
| 2023-06-07 | Baxter Healthcare | $1,351 | Long term medical supply or device loan | In-kind items and services | Hillrom - CP 150 Resting Electrocardiograph Device, Cardiology/Vascular Diseases | 2023 | |
| 2023-06-02 | Smith+Nephew, Inc. | $12 | Debt forgiveness | Cash or cash equivalent | NA Device, Enabling Technology | 2023 | |
| 2023-05-23 | ABBVIE INC. | $8,500 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2023 |
| 2023-05-23 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2023 |
| 2023-05-18 | ABBVIE INC. | $2,750 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2023 |
| 2023-05-17 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone DRd versus lenalidomide and Dexamethasone Rd in p | 2023 |
| 2023-05-15 | Boston Scientific Corporation | $169 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-05-11 | ABBVIE INC. | $2,684 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-04-05 | AstraZeneca Pharmaceuticals LP | $3,726 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2023 |
| 2023-04-02 | CardioFocus, Inc. | $150,000 | Long term medical supply or device loan | In-kind items and services | HeartLight System Device, Atrial Fibrillation | 2023 | |
| 2023-03-27 | CSL Behring | $500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2023 | |
| 2023-03-13 | Boston Scientific Corporation | $460 | Research payment | Cash or cash equivalent | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-02-21 | Boston Scientific Corporation | $750 | Research payment | In-kind items and services | General Brady Device, General Brady CRM | APPRAISE ATP | 2023 |
| 2023-02-15 | PFIZER INC. | $10,750 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-02-09 | ABBVIE INC. | $2,684 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-02-02 | ABBVIE INC. | $750 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-01-20 | AstraZeneca Pharmaceuticals LP | $66,433 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab | 2023 |
| 2023-01-11 | AstraZeneca Pharmaceuticals LP | $41,181 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2023 |
| 2023-01-10 | AstraZeneca UK Limited | $6,980 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphami | 2023 |
| 2023-01-06 | CSL Behring | $750 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2023 | |
| 2023-01-05 | ABBVIE INC. | $320 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2023 |
| 2023-01-03 | AstraZeneca Pharmaceuticals LP | $3,050 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L | 2023 |
| 2023-01-01 | Smith+Nephew, Inc. | $2,260 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Resection | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $2,260 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Resection | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $2,055 | Long term medical supply or device loan | In-kind items and services | LENS 4K Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $2,003 | Long term medical supply or device loan | In-kind items and services | LENS 4K Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $731 | Long term medical supply or device loan | In-kind items and services | N/A Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $527 | Long term medical supply or device loan | In-kind items and services | LENS 4K Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $527 | Long term medical supply or device loan | In-kind items and services | LENS 4K Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $527 | Long term medical supply or device loan | In-kind items and services | LENS 4K Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $525 | Long term medical supply or device loan | In-kind items and services | N/A Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $525 | Long term medical supply or device loan | In-kind items and services | N/A Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $467 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $467 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $410 | Long term medical supply or device loan | In-kind items and services | N/A Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $335 | Long term medical supply or device loan | In-kind items and services | Quantum 2 Device, Sports Med Resection | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $320 | Long term medical supply or device loan | In-kind items and services | N/A Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $320 | Long term medical supply or device loan | In-kind items and services | N/A Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $248 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Resection | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $248 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Resection | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $240 | Long term medical supply or device loan | In-kind items and services | DYONICS POWERMINI Device, Enabling Technology | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $240 | Long term medical supply or device loan | In-kind items and services | DYONICS POWERMINI Device, Enabling Technology | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $240 | Long term medical supply or device loan | In-kind items and services | DYONICS POWERMINI Device, Enabling Technology | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $105 | Long term medical supply or device loan | In-kind items and services | N/A Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $105 | Long term medical supply or device loan | In-kind items and services | N/A Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $105 | Long term medical supply or device loan | In-kind items and services | N/A Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $88 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $88 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $88 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $88 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $37 | Long term medical supply or device loan | In-kind items and services | MicroAire Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $34 | Long term medical supply or device loan | In-kind items and services | MicroAire Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $22 | Long term medical supply or device loan | In-kind items and services | MicroAire Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $22 | Long term medical supply or device loan | In-kind items and services | MicroAire Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $22 | Long term medical supply or device loan | In-kind items and services | MicroAire Device, Sports Med Visualization | 2023 | |
| 2023-01-01 | Smith+Nephew, Inc. | $9 | Long term medical supply or device loan | In-kind items and services | LENS 4K Device, Sports Med Visualization | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Duluth, MN, county St. Louis County, MN, state Minnesota; placed by its city name.
| Measure | Place (city or town) Duluth, MN | County St. Louis County, MN | State Minnesota |
|---|---|---|---|
| Population B01003 | 87,093 | 200,123 | 5,739,445 |
| Population, 2020 census P1 | 86,697 | 200,231 | 5,706,494 |
| Median age B01002 | 35.2 | 41.2 | 38.8 |
| Under 18 B01001 | 17.6% | 18.6% | 22.9% |
| 65 and over B01001 | 17.3% | 21.4% | 17.3% |
| Households B11001 | 37,447 | 87,115 | 2,307,955 |
| Foreign born B05002 | 3.1% | 1.9% | 8.7% |
| Median household income B19013 | $68,807 | $70,069 | $89,062 |
| Median family income B19113 | $102,608 | $95,686 | $113,993 |
| Per capita income B19301 | $41,503 | $41,302 | $48,237 |
| Poverty rate B17001 | 16.8% | 13.2% | 9.3% |
| Unemployment rate B23025 | 4.7% | 4.6% | 4.1% |
| Civilian labor force B23025 | 48,580 | 102,280 | 3,119,042 |
| Mean commute (minutes) B08013 | 17.3 | 19.9 | 22.7 |
| Bachelor's degree or higher B15003 | 44.0% | 33.6% | 39.4% |
| Housing units B25001 | 39,978 | 104,263 | 2,545,030 |
| Owner-occupied B25003 | 59.4% | 71.2% | 72.2% |
| Renters B25003 | 40.6% | 28.8% | 27.8% |
| Median home value B25077 | $242,700 | $221,400 | $329,300 |
| Median gross rent B25064 | $1,087 | $1,013 | $1,280 |
| White, not Hispanic B03002 | 86.6% | 89.5% | 75.9% |
| Black B03002 | 2.7% | 1.6% | 6.9% |
| Hispanic or Latino B03002 | 2.6% | 1.9% | 6.4% |
| Asian B03002 | 1.7% | 1.0% | 5.1% |
| American Indian and Alaska Native B03002 | 1.3% | 1.5% | 0.7% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Duluth, MN.
Comments